FindTrial
Sign In

Efficacy of I/v Nalbuphine v/s Iv Lignocain in Attanuation of Pressor Responseduring Laryngeoscopy and Intubation in Middle Age Patient Planned for Thyroid Surgery

Efficacy of IV Lignocaine Versus IV Nalbuphine for Attenuation of Pressor Response Diring Laryngoscopy and Intubation in Patients Planned for Thyroid Surgery

Status
UNKNOWN
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05298761
Enrollment
60
Registered
2022-03-28
Start date
2023-12-30
Completion date
2024-06-01
Last updated
2023-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodynamic Stability

Brief summary

Comparison of I/V nalbuphine versus I/V xylocain in attanuation of pressor response during intubation and laryngeoscopy in patients undergoing for thyroid surgery,selection of better supressor agent minimises the drug repated side effects like hypertention tachycardia but also helps in heamodynamically stability at induction.

Interventions

DRUGLignocaine

Inj lignocain and inj nalbuphine given to two groups of participants and effects of both drugs

Sponsors

Sheikh Zayed Medical College
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* middle age(18\_40) * Asa 1 and 2 * Non hypertensive * Thyroid patients * patient who gives consent

Exclusion criteria

* hypertensive * Asa 3 and 4 * Patient refusal

Design outcomes

Primary

MeasureTime frameDescription
Reduce stress response during intubation and hemodynamic stabilty10 minutesAssesment of Hemodynamic stability by observing vital signs
Achieve hemodynamic stabilty and smooth intubation10 minutesAssesment of hemodynamic stability by clinical examination of vital signs

Countries

Pakistan

Contacts

Primary ContactDr.amna Sarwar, Fcps
Dr.amnasabir@gmail.com03218337129

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026